{"id":2072,"date":"2026-06-18T16:56:01","date_gmt":"2026-06-18T16:56:01","guid":{"rendered":"https:\/\/one-peptides.com\/?p=2072"},"modified":"2026-10-04T10:27:29","modified_gmt":"2026-10-04T10:27:29","slug":"retatrutide-vs-tirzepatide-triple-vs-dual-agonism-in-anti-obesity-pharmacology","status":"publish","type":"post","link":"https:\/\/one-peptides.com\/de\/retatrutide-vs-tirzepatide-triple-vs-dual-agonism-in-anti-obesity-pharmacology\/","title":{"rendered":"Retatrutide vs Tirzepatide \u2014 triple vs dual agonism in anti-obesity pharmacology"},"content":{"rendered":"<div class=\"op-breadcrumbs\" style=\"margin:0 0 18px;font-size:13px;color:#6b7280;\"><div class=\"aioseo-breadcrumbs\"><span class=\"aioseo-breadcrumb\">\n\t<a href=\"https:\/\/one-peptides.com\/de\/\" title=\"Home\">Home<\/a>\n<\/span><span class=\"aioseo-breadcrumb-separator\">\u00bb<\/span><span class=\"aioseo-breadcrumb\">\n\t<a href=\"https:\/\/one-peptides.com\/de\/category\/metabolism\/\" title=\"Metabolic research\">Metabolic research<\/a>\n<\/span><span class=\"aioseo-breadcrumb-separator\">\u00bb<\/span><span class=\"aioseo-breadcrumb\">\n\tRetatrutide vs Tirzepatide \u2014 triple vs dual agonism in anti-obesity pharmacology\n<\/span><\/div><\/div>\n<h1><em><strong style=\"font-size: 16px;\">Regulatory note \u2014 a critical distinction in the status of the two peptides<\/strong><\/em><\/h1>\n<ul>\n<li><em><strong>Tirzepatide<\/strong> functions as a <strong>registered medicinal product<\/strong> (Mounjaro \u2014 T2D, FDA and EMA 2022; Zepbound \u2014 obesity, FDA 2023, EMA 2024) and as a <strong>research reagent (RUO)<\/strong> in laboratory distribution.<\/em><\/li>\n<li><em><strong>Retatrutide<\/strong> is not registered in any major jurisdiction \u2014 the phase III TRIUMPH programme (Eli Lilly) is ongoing. The peptide is available exclusively as a <strong>research reagent (RUO)<\/strong>.<\/em><\/li>\n<\/ul>\n<p>This text compares data from the <strong>clinical literature<\/strong>. It does not contain recommendations or medical advice.<\/p>\n<p>The comparison of <strong>retatrutide vs tirzepatide<\/strong> is a comparison of two consecutive steps in the evolution of incretin pharmacology. After GLP-1 receptor monoagonists (<a href=\"https:\/\/one-peptides.com\/semaglutide-what-do-we-know-from-clinical-trials\/\">semaglutide<\/a>, liraglutide), Eli Lilly developed two peptides with a broader receptor profile \u2014 first a GLP-1 + GIP dual agonist (<a href=\"https:\/\/one-peptides.com\/tirzepatide-dual-gip-glp-1-agonist-in-metabolism-research\/\">tirzepatide<\/a>, LY3298176), then a GLP-1 + GIP + glucagon tri-agonist (<a href=\"https:\/\/one-peptides.com\/retatrutide-triple-agonist-glp-1-gip-glucagon-in-clinical-trials\/\">retatrutide<\/a>, LY3437943).<\/p>\n<blockquote><p><strong>Lead definition<\/strong><\/p>\n<p><strong>Retatrutide<\/strong> (a GLP-1 \/ GIP \/ glucagon triple agonist) and <strong>tirzepatide<\/strong> (a GLP-1 \/ GIP dual agonist) are two Eli Lilly peptides representing consecutive steps in the evolution of incretin pharmacology. <strong>Tirzepatide is a registered medicine<\/strong> (Mounjaro, Zepbound) with full phase III data. <strong>Retatrutide remains in phase III<\/strong> of the TRIUMPH clinical trials.<\/p><\/blockquote>\n<blockquote><p><strong>Comparability of data \u2014 a head-to-head RCT of retatrutide vs tirzepatide has not been published.<\/strong> Every numerical comparison in this article must be read as an <strong>indirect literature-based comparison<\/strong>.<\/p><\/blockquote>\n<h2>The evolution of incretins \u2014 classification context<\/h2>\n<ul>\n<li><strong>Mono GLP-1<\/strong> \u2014 semaglutide (Ozempic, Wegovy, Rybelsus), liraglutide, exenatide.<\/li>\n<li><strong>Dual GLP-1 + GIP<\/strong> \u2014 tirzepatide (Mounjaro, Zepbound).<\/li>\n<li><strong>Tri GLP-1 + GIP + glucagon<\/strong> \u2014 retatrutide (phase III TRIUMPH).<\/li>\n<\/ul>\n<p>The sequence is not coincidental. GLP-1 and GIP are physiological partners in the incretin effect \u2014 together they account for over 60% of the insulin response to a meal. Adding GIP to GLP-1 (tirzepatide) was a logical complement to physiology. Adding <strong>glucagon<\/strong> (retatrutide) went beyond the classic incretin axis \u2014 glucagon is not an incretin hormone but an energy-mobilising hormone. A full overview of the incretin axis is provided in the article on <a href=\"https:\/\/one-peptides.com\/glp-1-gip-glucagon-how-incretins-regulate-metabolism\/\">the incretins GLP-1, GIP and glucagon<\/a>.<\/p>\n<h2>Mechanism \u2014 what the addition of glucagon brings<\/h2>\n<h3>Tirzepatide \u2014 GLP-1 + GIP synergy<\/h3>\n<p>Tirzepatide activates two incretin receptors simultaneously and is the first clinically advanced GIP\/GLP-1 dual agonist (Coskun et al. 2018). Activity at <strong>GLP-1R<\/strong> is responsible for glucose-dependent insulin secretion, suppression of glucagon secretion, delayed gastric emptying and appetite reduction. Activity at <strong>GIPR<\/strong> brings a synergistic increase in insulin secretion as well as modulation of adipose tissue metabolism.<\/p>\n<p>In a head-to-head trial with the monoagonist semaglutide (SURPASS-2, Frias et al. 2021), tirzepatide produced a stronger reduction in HbA1c and a greater body weight reduction with a comparable adverse-event profile. Available in the catalogue as <a href=\"https:\/\/one-peptides.com\/product\/glp-1gip-5-mg-pen\/\">GLP-1+GIP 5mg PEN<\/a>.<\/p>\n<h3>Retatrutide \u2014 addition of the glucagon pathway (GCGR)<\/h3>\n<p>Retatrutide retains activity at GLP-1R and GIPR while adding <strong>partial activation of the glucagon receptor (GCGR)<\/strong>. The potencies published by Coskun et al. (2022): <strong>~94%<\/strong> of the potency of native GLP-1 at GLP-1R, <strong>~135%<\/strong> of native GIP at GIPR (stronger than the native ligand), <strong>~52%<\/strong> of native glucagon at GCGR (weaker). The chosen proportions mean that the hypoglycaemic pathway (GLP-1 + GIP) more than compensates for the hyperglycaemic pathway (glucagon).<\/p>\n<p>The informal shorthand used for retatrutide in online searches is explained in a separate entry: <a href=\"https:\/\/one-peptides.com\/reta-for-weight-loss-diet-what-does-that-mean\/\">\u201creta\u201d: where the name comes from<\/a>.<\/p>\n<p>In pharmacology, a <strong>partial GCGR agonist<\/strong> brings three effects desirable in obesity therapy that neither mono- nor dual-agonists provide:<\/p>\n<ul>\n<li><strong>Increased energy expenditure<\/strong> \u2014 thermogenesis in brown adipose tissue<\/li>\n<li><strong>Hepatic lipolysis<\/strong> \u2014 reduction of liver fat content. Relevant in the context of <strong>MASLD\/MASH<\/strong><\/li>\n<li><strong>Appetite modulation<\/strong> \u2014 central, additional to the effects of GLP-1 and GIP<\/li>\n<\/ul>\n<p>In the One Peptides catalogue, available as <a href=\"https:\/\/one-peptides.com\/product\/triple-g-20-mg-pen\/\">Triple G 20mg PEN<\/a> or as a separate lyophilisate.<\/p>\n<h2>What the studies say \u2014 phase III SURMOUNT vs phase II Jastreboff 2023<\/h2>\n<h3>Tirzepatide \u2014 phase III + registration<\/h3>\n<ul>\n<li><strong>SURPASS<\/strong> (type 2 diabetes) \u2014 <strong>SURPASS-2<\/strong> (Frias et al. 2021) head-to-head with semaglutide 1 mg in T2D.<\/li>\n<li><strong>SURMOUNT<\/strong> (obesity) \u2014 <strong>SURMOUNT-1<\/strong> (Jastreboff et al. 2022) assessed tirzepatide in obesity without T2D, n = 2539, 72 weeks. Mean body weight reduction: <strong>~22.5%<\/strong> in the 15 mg group vs 2.4% in the placebo group.<\/li>\n<\/ul>\n<p>On the basis of these data, tirzepatide obtained registration as <strong>Mounjaro<\/strong> (T2D, FDA and EMA 2022) and <strong>Zepbound<\/strong> (obesity, FDA 2023, EMA 2024).<\/p>\n<h3>Retatrutide \u2014 phase II + phase III in progress<\/h3>\n<ul>\n<li><strong>Phase II in obesity<\/strong> (Jastreboff et al. 2023, NEJM) \u2014 n = 338, 48 weeks. Mean body weight reduction: <strong>~24.2%<\/strong> in the 12 mg group vs 2.1% in the placebo group. The reduction curve <strong>had not reached a plateau<\/strong> by week 48.<\/li>\n<li><strong>Phase II in T2D<\/strong> (Rosenstock et al. 2023, Lancet) \u2014 HbA1c reduction of up to <strong>~2.02%<\/strong> in the highest-dose group, body weight reduction of up to ~16.9%.<\/li>\n<\/ul>\n<p>The full <strong>phase III TRIUMPH programme<\/strong>, started in 2022, comprises multiple trials. At the time of writing, there are <strong>no<\/strong> full, peer-reviewed publications of phase III results.<\/p>\n<blockquote><p><strong>Interpretative note<\/strong> \u2014 the numerical figures come from <strong>different phases<\/strong> of clinical trials. Retatrutide is described by <strong>phase II<\/strong>, tirzepatide by <strong>phase III<\/strong> + registration. The comparison is indirect in nature.<\/p><\/blockquote>\n<h2>Comparison table retatrutide vs tirzepatide \u2014 full overview<\/h2>\n<table style=\"min-width: 100px; border-collapse: collapse; border-spacing: 0px; width: 100%;\" data-border-width=\"1\">\n<tbody>\n<tr>\n<th style=\"border: 1px solid #d1d5db; padding: 8px 12px;\"><strong>Characteristic<\/strong><\/th>\n<th style=\"border: 1px solid #d1d5db; padding: 8px 12px;\"><strong>Retatrutide<\/strong><\/th>\n<th style=\"border: 1px solid #d1d5db; padding: 8px 12px;\"><strong>Tirzepatide<\/strong><\/th>\n<\/tr>\n<tr>\n<td style=\"border: 1px solid #d1d5db; padding: 8px 12px;\">Internal designation<\/td>\n<td style=\"border: 1px solid #d1d5db; padding: 8px 12px;\">LY3437943<\/td>\n<td style=\"border: 1px solid #d1d5db; padding: 8px 12px;\">LY3298176<\/td>\n<\/tr>\n<tr>\n<td style=\"border: 1px solid #d1d5db; padding: 8px 12px;\">Pharmacological class<\/td>\n<td style=\"border: 1px solid #d1d5db; padding: 8px 12px;\">Tri-agonist (GLP-1R + GIPR + GCGR)<\/td>\n<td style=\"border: 1px solid #d1d5db; padding: 8px 12px;\">Dual-agonist (GLP-1R + GIPR)<\/td>\n<\/tr>\n<tr>\n<td style=\"border: 1px solid #d1d5db; padding: 8px 12px;\">Architecture<\/td>\n<td style=\"border: 1px solid #d1d5db; padding: 8px 12px;\">39 aa peptide, once\/week, s.c.<\/td>\n<td style=\"border: 1px solid #d1d5db; padding: 8px 12px;\">39 aa peptide, once\/week, s.c.<\/td>\n<\/tr>\n<tr>\n<td style=\"border: 1px solid #d1d5db; padding: 8px 12px;\">Manufacturer<\/td>\n<td style=\"border: 1px solid #d1d5db; padding: 8px 12px;\">Eli Lilly<\/td>\n<td style=\"border: 1px solid #d1d5db; padding: 8px 12px;\">Eli Lilly<\/td>\n<\/tr>\n<tr>\n<td style=\"border: 1px solid #d1d5db; padding: 8px 12px;\">Half-life<\/td>\n<td style=\"border: 1px solid #d1d5db; padding: 8px 12px;\">~6 days<\/td>\n<td style=\"border: 1px solid #d1d5db; padding: 8px 12px;\">~5 days<\/td>\n<\/tr>\n<tr>\n<td style=\"border: 1px solid #d1d5db; padding: 8px 12px;\">Registration status<\/td>\n<td style=\"border: 1px solid #d1d5db; padding: 8px 12px;\">Phase III TRIUMPH (not registered)<\/td>\n<td style=\"border: 1px solid #d1d5db; padding: 8px 12px;\"><strong>Registered medicine<\/strong> \u2014 Mounjaro, Zepbound<\/td>\n<\/tr>\n<tr>\n<td style=\"border: 1px solid #d1d5db; padding: 8px 12px;\">Effect on the liver (MASLD)<\/td>\n<td style=\"border: 1px solid #d1d5db; padding: 8px 12px;\">Hepatic lipolysis via GCGR agonism<\/td>\n<td style=\"border: 1px solid #d1d5db; padding: 8px 12px;\">Modulation via GIP<\/td>\n<\/tr>\n<tr>\n<td style=\"border: 1px solid #d1d5db; padding: 8px 12px;\">Energy expenditure<\/td>\n<td style=\"border: 1px solid #d1d5db; padding: 8px 12px;\">Increase via GCGR thermogenesis<\/td>\n<td style=\"border: 1px solid #d1d5db; padding: 8px 12px;\">No direct thermogenesis<\/td>\n<\/tr>\n<tr>\n<td style=\"border: 1px solid #d1d5db; padding: 8px 12px;\">Heart rate<\/td>\n<td style=\"border: 1px solid #d1d5db; padding: 8px 12px;\">Greater increase (GCGR)<\/td>\n<td style=\"border: 1px solid #d1d5db; padding: 8px 12px;\">Slight increase<\/td>\n<\/tr>\n<tr>\n<td style=\"border: 1px solid #d1d5db; padding: 8px 12px;\">Gastrointestinal profile<\/td>\n<td style=\"border: 1px solid #d1d5db; padding: 8px 12px;\">Higher nausea at higher doses (25\u201360%)<\/td>\n<td style=\"border: 1px solid #d1d5db; padding: 8px 12px;\">Nausea 25\u201331% in phase III<\/td>\n<\/tr>\n<tr>\n<td style=\"border: 1px solid #d1d5db; padding: 8px 12px;\">Head-to-head profile<\/td>\n<td style=\"border: 1px solid #d1d5db; padding: 8px 12px;\">No head-to-head with tirzepatide<\/td>\n<td style=\"border: 1px solid #d1d5db; padding: 8px 12px;\">Head-to-head with semaglutide (SURPASS-2)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>Profiles and limitations \u2014 what we know and what we do not<\/h2>\n<p><strong>Tirzepatide<\/strong> has a mature safety profile from phase III + registration. Gastrointestinal adverse events predominate (nausea, diarrhoea, vomiting). Rare signals: pancreatitis, gallbladder disease, contraindication in people with a personal or family history of medullary thyroid carcinoma.<\/p>\n<p><strong>Retatrutide<\/strong> has a profile described on the basis of phase II. The Jastreboff 2023 data indicate higher nausea at higher doses (25\u201360%), a greater increase in heart rate (mechanism: GCGR) and a signal of a slight increase in glycaemia in some subgroups.<\/p>\n<p><strong>What we do not know:<\/strong> there is no head-to-head RCT of retatrutide vs tirzepatide; the long-term cardiovascular profile of retatrutide requires multi-year observation; full phase III TRIUMPH data \u2014 publications expected from 2025.<\/p>\n<h2>FAQ \u2014 frequently asked questions<\/h2>\n<h3>Retatrutide or tirzepatide \u2014 which is stronger for body weight reduction?<\/h3>\n<p>An <strong>indirect<\/strong> comparison points to a slightly higher body weight reduction with retatrutide (~24.2% in phase II, 48 weeks) than with tirzepatide (~22.5% in phase III SURMOUNT-1, 72 weeks). The figures come from <strong>different phases<\/strong> of clinical trials. A head-to-head RCT has not been published to date.<\/p>\n<h3>What does glucagon add to the metabolic effect of an incretin peptide?<\/h3>\n<p>Partial GCGR activation in retatrutide brings three effects: <strong>increased energy expenditure<\/strong> (thermogenesis), <strong>hepatic lipolysis<\/strong> (relevant in MASLD\/MASH) and <strong>additional appetite modulation<\/strong>.<\/p>\n<h3>Which peptide is better studied?<\/h3>\n<p><strong>Tirzepatide<\/strong> \u2014 a full phase III programme (SURPASS, SURMOUNT), registration in two indications (Mounjaro 2022, Zepbound 2023). Retatrutide has a phase II from 2023 and the phase III TRIUMPH programme in progress.<\/p>\n<h3>When might retatrutide be registered?<\/h3>\n<p>After completion of the main phase III TRIUMPH trials, publication of the results, and submission of a registration application to the FDA and EMA \u2014 realistically <strong>in 2027\u20132028<\/strong> (a pathway analogous to tirzepatide).<\/p>\n<p><script type=\"application\/ld+json\">\n{\n  \"@context\": \"https:\/\/schema.org\",\n  \"@type\": \"FAQPage\",\n  \"mainEntity\": [\n    {\"@type\": \"Question\", \"name\": \"Retatrutide or tirzepatide \u2014 which is stronger for body weight reduction?\", \"acceptedAnswer\": {\"@type\": \"Answer\", \"text\": \"An indirect comparison points to a slightly higher body weight reduction with retatrutide (~24.2% in phase II, 48 weeks) than with tirzepatide (~22.5% in phase III SURMOUNT-1, 72 weeks). The figures come from different phases of clinical trials. A head-to-head RCT has not been published to date.\"}},\n    {\"@type\": \"Question\", \"name\": \"What does glucagon add to the metabolic effect of an incretin peptide?\", \"acceptedAnswer\": {\"@type\": \"Answer\", \"text\": \"Partial GCGR activation in retatrutide brings three effects that GLP-1 + GIP dual-agonists do not provide: increased energy expenditure (thermogenesis in brown adipose tissue), hepatic lipolysis (relevant in MASLD\/MASH) and additional appetite modulation.\"}},\n    {\"@type\": \"Question\", \"name\": \"Which peptide is better studied?\", \"acceptedAnswer\": {\"@type\": \"Answer\", \"text\": \"Tirzepatide \u2014 a full phase III programme (SURPASS, SURMOUNT), registration in two indications (Mounjaro 2022, Zepbound 2023), head-to-head with semaglutide (SURPASS-2). Retatrutide has a phase II from 2023 and the phase III TRIUMPH programme in progress.\"}},\n    {\"@type\": \"Question\", \"name\": \"When might retatrutide be registered?\", \"acceptedAnswer\": {\"@type\": \"Answer\", \"text\": \"After completion of the main phase III TRIUMPH trials, publication of the results, and submission of a registration application to the FDA and EMA \u2014 realistically in 2027\u20132028.\"}}\n  ]\n}\n<\/script><\/p>\n<h2>Related content in the knowledge base<\/h2>\n<ul>\n<li><a href=\"https:\/\/one-peptides.com\/retatrutide-triple-agonist-glp-1-gip-glucagon-in-clinical-trials\/\">Retatrutide \u2014 a triple agonist in research<\/a><\/li>\n<li><a href=\"https:\/\/one-peptides.com\/tirzepatide-dual-gip-glp-1-agonist-in-metabolism-research\/\">Tirzepatide \u2014 a GIP\/GLP-1 dual agonist<\/a><\/li>\n<li><a href=\"https:\/\/one-peptides.com\/semaglutide-vs-retatrutide-comparison-of-mechanisms-and-clinical-outcomes\/\">Semaglutide vs Retatrutide \u2014 comparison of mechanisms<\/a><\/li>\n<li><a href=\"https:\/\/one-peptides.com\/glp-1-gip-glucagon-how-incretins-regulate-metabolism\/\">GLP-1, GIP, glucagon \u2014 how the incretins work<\/a><\/li>\n<li><a href=\"https:\/\/one-peptides.com\/semaglutide-what-do-we-know-from-clinical-trials\/\">Semaglutide \u2014 what we know from clinical trials<\/a><\/li>\n<li><a href=\"https:\/\/one-peptides.com\/cagrisema-semaglutide-cagrilintide-combination-in-clinical-obesity-research\/\">CagriSema \u2014 semaglutide + cagrilintide<\/a><\/li>\n<li><a href=\"https:\/\/one-peptides.com\/glp-1-peptides-in-metabolic-research\/\">GLP-1 peptides in metabolism research<\/a><\/li>\n<\/ul>\n<h2>Retatrutide and tirzepatide as research reagents<\/h2>\n<blockquote><p><strong>RUO note \u2014 Research Use Only<\/strong><\/p>\n<p>Both peptides in the One Peptides catalogue function as <strong>research reagents intended for laboratory research use only<\/strong>. They are not medicines, they are not dietary supplements and they are not intended for use in humans.<\/p><\/blockquote>\n<p>In the research-reagent catalogue, retatrutide is available as <a href=\"https:\/\/one-peptides.com\/product\/triple-g-20-mg-pen\/\">Triple G 20mg PEN<\/a> or as a separate lyophilisate, and tirzepatide as <a href=\"https:\/\/one-peptides.com\/product\/glp-1gip-5-mg-pen\/\">GLP-1+GIP PEN<\/a>. Catalogue standards: <strong>HPLC \u2265 98%<\/strong>, <strong>MS<\/strong>, <strong>COA<\/strong> for every batch, <strong>cold chain<\/strong>. A full description is given in <a href=\"https:\/\/one-peptides.com\/quality-testing-and-certificates\/\">quality testing and certificates<\/a>.<\/p>\n<p>A separate lyophilized product is <a href=\"https:\/\/one-peptides.com\/product\/retatrutide-5-mg\/\">Retatrutide (Triple G) 5 mg<\/a>, offered exclusively as a Research Use Only reagent.<\/p>\n<h2>Summary<\/h2>\n<p>The comparison of <strong>retatrutide vs tirzepatide<\/strong> is a comparison of two consecutive steps in the evolution of incretin pharmacology \u2014 from dual agonism to tri-agonism. Adding GCGR activity in retatrutide brings <strong>increased energy expenditure<\/strong>, <strong>hepatic lipolysis<\/strong> and <strong>additional appetite modulation<\/strong>.<\/p>\n<p>The most significant asymmetry in the comparison is the <strong>different stage of clinical development<\/strong>: tirzepatide has a full phase III + registration, while retatrutide has a phase II and the phase III TRIUMPH programme in progress. The indirect comparison of the figures (~24.2% vs ~22.5% weight reduction) is <strong>cautious<\/strong> and does not replace a head-to-head RCT.<\/p>\n<blockquote><p><strong>Final disclaimer<\/strong><\/p>\n<p>One-Peptides products are reagents for laboratory research (Research Use Only). They are not medicines, dietary supplements or products for human consumption. <strong>Tirzepatide<\/strong> is a registered medicine (Mounjaro, Zepbound) \u2014 it requires a medical prescription. <strong>Retatrutide<\/strong> is in phase III TRIUMPH; at the time of writing it is not registered. This text is educational and review in nature.<\/p><\/blockquote>\n<h2>Bibliography<\/h2>\n<ol>\n<li>Coskun T, Sloop KW, Loghin C, et al. (2018). <a href=\"https:\/\/doi.org\/10.1016\/j.molmet.2018.09.009\" target=\"_blank\" rel=\"noopener noreferrer\"><cite>LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus<\/cite><\/a><\/li>\n<li>Coskun T, Urva S, Roell WC, et al. (2022). <a href=\"https:\/\/doi.org\/10.1016\/j.cmet.2022.07.013\" target=\"_blank\" rel=\"noopener noreferrer\"><cite>LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss<\/cite><\/a><\/li>\n<li>Frias JP, Davies MJ, Rosenstock J, et al. (2021). <a href=\"https:\/\/doi.org\/10.1056\/NEJMoa2107519\" target=\"_blank\" rel=\"noopener noreferrer\"><cite>Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2)<\/cite><\/a><\/li>\n<li>Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). <a href=\"https:\/\/doi.org\/10.1056\/NEJMoa2206038\" target=\"_blank\" rel=\"noopener noreferrer\"><cite>Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1)<\/cite><\/a><\/li>\n<li>Jastreboff AM, Kaplan LM, Fr\u00edas JP, et al. (2023). <a href=\"https:\/\/doi.org\/10.1056\/NEJMoa2301972\" target=\"_blank\" rel=\"noopener noreferrer\"><cite>Triple-hormone-receptor agonist retatrutide for obesity \u2014 a phase 2 trial<\/cite><\/a><\/li>\n<li>Rosenstock J, Frias J, Jastreboff AM, et al. (2023). <a href=\"https:\/\/doi.org\/10.1016\/S0140-6736(23)01053-X\" target=\"_blank\" rel=\"noopener noreferrer\"><cite>Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes \u2014 a phase 2 trial<\/cite><\/a><\/li>\n<li>Min T, Bain SC (2021). <a href=\"https:\/\/doi.org\/10.1007\/s13300-020-00981-0\" target=\"_blank\" rel=\"noopener noreferrer\"><cite>The role of tirzepatide, dual GIP and GLP-1 receptor agonist, in the management of type 2 diabetes \u2014 the SURPASS clinical trials<\/cite><\/a><\/li>\n<\/ol>\n<p><!-- onep-post-reviewer-banner:start --><\/p>\n<div class=\"author-box onep-post-reviewer-banner\" style=\"border-left: 4px solid #958e09; background: #f9fafb; padding: 16px 20px; margin: 32px 0; border-radius: 4px;\">\n<p style=\"margin: 0 0 8px 0; font-size: 14px; line-height: 1.5;\"><strong>Pharmaceutical review:<\/strong> <a href=\"https:\/\/one-peptides.com\/team-aneta-kropicka\/\">MPharm Aneta Kropicka<\/a><br \/>\n<em>Pharmaceutical reviewer and sports supplementation expert.<\/em><br \/>\nMaster of Pharmacy with 12 years of professional experience, graduate of the Medical University of \u0141\u00f3d\u017a (2014). Verifies One Peptides content for pharmacology, clinical dosing, and regulatory compliance across RUO \/ dietary supplement \/ drug frameworks.<\/p>\n<p style=\"margin: 0; font-size: 12px; color: #6b7280;\"><small>Published: <time datetime=\"2026-06-18\">2026-06-18<\/time> \u2022 Last updated: <time datetime=\"2026-06-18\">2026-06-18<\/time><\/small><\/p>\n<\/div>\n<p><!-- onep-post-reviewer-banner:end --><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Regulatory note \u2014 a critical distinction in the status of the two peptides Tirzepatide functions as a registered medicinal product (Mounjaro \u2014 T2D, FDA and EMA 2022; Zepbound \u2014 obesity, FDA 2023, EMA 2024) and as a research reagent (RUO) in laboratory distribution. Retatrutide is not registered in any major jurisdiction \u2014 the phase III [&hellip;]<\/p>\n","protected":false},"author":31,"featured_media":2073,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":"","_members_access_role":[],"_members_access_error":""},"categories":[152],"tags":[],"class_list":["post-2072","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-metabolism"],"acf":[],"aioseo_notices":[],"aioseo_head":"\n\t\t<!-- All in One SEO Pro 5.0.3 - aioseo.com -->\n\t<meta name=\"description\" content=\"Retatrutide vs. Tirzepatide \u2014 a comparison of the mechanism and clinical data. GLP-1\/GIP\/glucagon tri-agonist and GLP-1\/GIP dual agonist, Mounjaro\/Zepbound\" \/>\n\t<meta name=\"robots\" content=\"max-image-preview:large\" \/>\n\t<meta name=\"author\" content=\"Bartosz Bartczak\"\/>\n\t<link rel=\"canonical\" href=\"https:\/\/one-peptides.com\/de\/retatrutide-vs-tirzepatide-triple-vs-dual-agonism-in-anti-obesity-pharmacology\/\" \/>\n\t\t<meta name=\"generator\" content=\"All in One SEO Pro (AIOSEO) 5.0.3\" \/>\n\t\t<meta property=\"og:locale\" content=\"de_DE\" \/>\n\t\t<meta property=\"og:site_name\" content=\"One-Peptides -\" \/>\n\t\t<meta property=\"og:type\" content=\"article\" \/>\n\t\t<meta property=\"og:title\" content=\"Retatrutide vs. Tirzepatide \u2014 Tri-Agonist vs. Dual Agonist\" \/>\n\t\t<meta property=\"og:description\" content=\"Retatrutide vs. Tirzepatide \u2014 a comparison of the mechanism and clinical data. GLP-1\/GIP\/glucagon tri-agonist and GLP-1\/GIP dual agonist, Mounjaro\/Zepbound\" \/>\n\t\t<meta property=\"og:url\" content=\"https:\/\/one-peptides.com\/de\/retatrutide-vs-tirzepatide-triple-vs-dual-agonism-in-anti-obesity-pharmacology\/\" \/>\n\t\t<meta property=\"og:image\" content=\"https:\/\/one-peptides.com\/wp-content\/uploads\/2026\/06\/triple-g-vs-glp1gip.webp\" \/>\n\t\t<meta property=\"og:image:secure_url\" content=\"https:\/\/one-peptides.com\/wp-content\/uploads\/2026\/06\/triple-g-vs-glp1gip.webp\" \/>\n\t\t<meta property=\"og:image:width\" content=\"1536\" \/>\n\t\t<meta property=\"og:image:height\" content=\"1024\" \/>\n\t\t<meta property=\"article:published_time\" content=\"2026-06-18T16:56:01+00:00\" \/>\n\t\t<meta property=\"article:modified_time\" content=\"2026-10-04T10:27:29+00:00\" \/>\n\t\t<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n\t\t<meta name=\"twitter:title\" content=\"Retatrutide vs. Tirzepatide \u2014 Tri-Agonist vs. Dual Agonist\" \/>\n\t\t<meta name=\"twitter:description\" content=\"Retatrutide vs. Tirzepatide \u2014 a comparison of the mechanism and clinical data. GLP-1\/GIP\/glucagon tri-agonist and GLP-1\/GIP dual agonist, Mounjaro\/Zepbound\" \/>\n\t\t<meta name=\"twitter:image\" content=\"https:\/\/one-peptides.com\/wp-content\/uploads\/2026\/06\/triple-g-vs-glp1gip.webp\" \/>\n\t\t<script type=\"application\/ld+json\" class=\"aioseo-schema\">\n\t\t\t{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"BlogPosting\",\"@id\":\"https:\\\/\\\/one-peptides.com\\\/de\\\/retatrutide-vs-tirzepatide-triple-vs-dual-agonism-in-anti-obesity-pharmacology\\\/#blogposting\",\"name\":\"Retatrutide vs. Tirzepatide \\u2014 Tri-Agonist vs. Dual Agonist\",\"headline\":\"Retatrutide vs Tirzepatide \\u2014 triple vs dual agonism in anti-obesity pharmacology\",\"author\":{\"@id\":\"https:\\\/\\\/one-peptides.com\\\/de\\\/team-bartosz-bartczak\\\/#person\"},\"publisher\":{\"@id\":\"https:\\\/\\\/one-peptides.com\\\/de\\\/#organization\"},\"image\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/one-peptides.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/triple-g-vs-glp1gip.webp\",\"width\":1536,\"height\":1024},\"datePublished\":\"2026-06-18T16:56:01+00:00\",\"dateModified\":\"2026-10-04T10:27:29+00:00\",\"inLanguage\":\"de-DE\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/one-peptides.com\\\/de\\\/retatrutide-vs-tirzepatide-triple-vs-dual-agonism-in-anti-obesity-pharmacology\\\/#webpage\"},\"isPartOf\":{\"@id\":\"https:\\\/\\\/one-peptides.com\\\/de\\\/retatrutide-vs-tirzepatide-triple-vs-dual-agonism-in-anti-obesity-pharmacology\\\/#webpage\"},\"articleSection\":\"Metabolic research\",\"wordCount\":1672,\"reviewedBy\":{\"@id\":\"https:\\\/\\\/one-peptides.com\\\/de\\\/team-aneta-kropicka\\\/#person\"}},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/one-peptides.com\\\/de\\\/retatrutide-vs-tirzepatide-triple-vs-dual-agonism-in-anti-obesity-pharmacology\\\/#breadcrumblist\",\"itemListElement\":[{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/one-peptides.com\\\/de\\\/#listItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/one-peptides.com\\\/de\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/one-peptides.com\\\/de\\\/category\\\/metabolism\\\/#listItem\",\"name\":\"Metabolic research\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/one-peptides.com\\\/de\\\/category\\\/metabolism\\\/#listItem\",\"position\":2,\"name\":\"Metabolic research\",\"item\":\"https:\\\/\\\/one-peptides.com\\\/de\\\/category\\\/metabolism\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/one-peptides.com\\\/de\\\/retatrutide-vs-tirzepatide-triple-vs-dual-agonism-in-anti-obesity-pharmacology\\\/#listItem\",\"name\":\"Retatrutide vs Tirzepatide \\u2014 triple vs dual agonism in anti-obesity pharmacology\"},\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/one-peptides.com\\\/de\\\/#listItem\",\"name\":\"Home\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/one-peptides.com\\\/de\\\/retatrutide-vs-tirzepatide-triple-vs-dual-agonism-in-anti-obesity-pharmacology\\\/#listItem\",\"position\":3,\"name\":\"Retatrutide vs Tirzepatide \\u2014 triple vs dual agonism in anti-obesity pharmacology\",\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/one-peptides.com\\\/de\\\/category\\\/metabolism\\\/#listItem\",\"name\":\"Metabolic research\"}}]},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/one-peptides.com\\\/de\\\/#organization\",\"name\":\"One-Peptides\",\"url\":\"https:\\\/\\\/one-peptides.com\\\/de\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/one-peptides.com\\\/wp-content\\\/uploads\\\/2024\\\/09\\\/cropped-Image-1-e1751599136894.png\",\"@id\":\"https:\\\/\\\/one-peptides.com\\\/de\\\/retatrutide-vs-tirzepatide-triple-vs-dual-agonism-in-anti-obesity-pharmacology\\\/#organizationLogo\",\"width\":291,\"height\":113},\"image\":{\"@id\":\"https:\\\/\\\/one-peptides.com\\\/de\\\/retatrutide-vs-tirzepatide-triple-vs-dual-agonism-in-anti-obesity-pharmacology\\\/#organizationLogo\"},\"legalName\":\"Joscur Limited\",\"sameAs\":[\"https:\\\/\\\/www.instagram.com\\\/one_peptides\\\/\"],\"contactPoint\":{\"@type\":\"ContactPoint\",\"email\":\"contact@one-peptides.com\",\"contactType\":\"customer service\"},\"parentOrganization\":{\"@type\":\"Organization\",\"name\":\"Joscur Limited\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/one-peptides.com\\\/de\\\/team-bartosz-bartczak\\\/#person\",\"url\":\"https:\\\/\\\/one-peptides.com\\\/de\\\/team-bartosz-bartczak\\\/\",\"name\":\"Bartosz Bartczak\",\"image\":{\"@type\":\"ImageObject\",\"@id\":\"https:\\\/\\\/one-peptides.com\\\/de\\\/retatrutide-vs-tirzepatide-triple-vs-dual-agonism-in-anti-obesity-pharmacology\\\/#authorImage\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/18c5ebea790bc7a8bd4088066983b1a92e5db957aa4e5888766fe20b92c9cfe6?s=96&d=mm&r=g\",\"width\":96,\"height\":96,\"caption\":\"Bartosz Bartczak\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/one-peptides.com\\\/de\\\/team-aneta-kropicka\\\/#person\",\"name\":\"Aneta Kropicka\",\"honorificPrefix\":\"M.Pharm.\",\"url\":\"https:\\\/\\\/one-peptides.com\\\/de\\\/team-aneta-kropicka\\\/\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/one-peptides.com\\\/de\\\/retatrutide-vs-tirzepatide-triple-vs-dual-agonism-in-anti-obesity-pharmacology\\\/#webpage\",\"url\":\"https:\\\/\\\/one-peptides.com\\\/de\\\/retatrutide-vs-tirzepatide-triple-vs-dual-agonism-in-anti-obesity-pharmacology\\\/\",\"name\":\"Retatrutide vs. Tirzepatide \\u2014 Tri-Agonist vs. Dual Agonist\",\"description\":\"Retatrutide vs. Tirzepatide \\u2014 a comparison of the mechanism and clinical data. GLP-1\\\/GIP\\\/glucagon tri-agonist and GLP-1\\\/GIP dual agonist, Mounjaro\\\/Zepbound\",\"inLanguage\":\"de-DE\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/one-peptides.com\\\/de\\\/#website\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/one-peptides.com\\\/de\\\/retatrutide-vs-tirzepatide-triple-vs-dual-agonism-in-anti-obesity-pharmacology\\\/#breadcrumblist\"},\"author\":{\"@id\":\"https:\\\/\\\/one-peptides.com\\\/de\\\/team-bartosz-bartczak\\\/#person\"},\"creator\":{\"@id\":\"https:\\\/\\\/one-peptides.com\\\/de\\\/team-bartosz-bartczak\\\/#person\"},\"image\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/one-peptides.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/triple-g-vs-glp1gip.webp\",\"@id\":\"https:\\\/\\\/one-peptides.com\\\/de\\\/retatrutide-vs-tirzepatide-triple-vs-dual-agonism-in-anti-obesity-pharmacology\\\/#mainImage\",\"width\":1536,\"height\":1024},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/one-peptides.com\\\/de\\\/retatrutide-vs-tirzepatide-triple-vs-dual-agonism-in-anti-obesity-pharmacology\\\/#mainImage\"},\"datePublished\":\"2026-06-18T16:56:01+00:00\",\"dateModified\":\"2026-10-04T10:27:29+00:00\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/one-peptides.com\\\/de\\\/#website\",\"url\":\"https:\\\/\\\/one-peptides.com\\\/de\\\/\",\"name\":\"One-Peptides\",\"inLanguage\":\"de-DE\",\"publisher\":{\"@id\":\"https:\\\/\\\/one-peptides.com\\\/de\\\/#organization\"}}]}\n\t\t<\/script>\n\t\t<!-- All in One SEO Pro -->\r\n\t\t<title>Retatrutide vs. Tirzepatide \u2014 Tri-Agonist vs. Dual Agonist<\/title>\n\n","aioseo_head_json":{"title":"Retatrutide vs. Tirzepatide \u2014 Tri-Agonist vs. Dual Agonist","description":"Retatrutide vs. Tirzepatide \u2014 a comparison of the mechanism and clinical data. GLP-1\/GIP\/glucagon tri-agonist and GLP-1\/GIP dual agonist, Mounjaro\/Zepbound","canonical_url":"https:\/\/one-peptides.com\/de\/retatrutide-vs-tirzepatide-triple-vs-dual-agonism-in-anti-obesity-pharmacology\/","robots":"max-image-preview:large","keywords":"","webmasterTools":{"miscellaneous":""},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"BlogPosting","@id":"https:\/\/one-peptides.com\/de\/retatrutide-vs-tirzepatide-triple-vs-dual-agonism-in-anti-obesity-pharmacology\/#blogposting","name":"Retatrutide vs. Tirzepatide \u2014 Tri-Agonist vs. Dual Agonist","headline":"Retatrutide vs Tirzepatide \u2014 triple vs dual agonism in anti-obesity pharmacology","author":{"@id":"https:\/\/one-peptides.com\/de\/team-bartosz-bartczak\/#person"},"publisher":{"@id":"https:\/\/one-peptides.com\/de\/#organization"},"image":{"@type":"ImageObject","url":"https:\/\/one-peptides.com\/wp-content\/uploads\/2026\/06\/triple-g-vs-glp1gip.webp","width":1536,"height":1024},"datePublished":"2026-06-18T16:56:01+00:00","dateModified":"2026-10-04T10:27:29+00:00","inLanguage":"de-DE","mainEntityOfPage":{"@id":"https:\/\/one-peptides.com\/de\/retatrutide-vs-tirzepatide-triple-vs-dual-agonism-in-anti-obesity-pharmacology\/#webpage"},"isPartOf":{"@id":"https:\/\/one-peptides.com\/de\/retatrutide-vs-tirzepatide-triple-vs-dual-agonism-in-anti-obesity-pharmacology\/#webpage"},"articleSection":"Metabolic research","wordCount":1672,"reviewedBy":{"@id":"https:\/\/one-peptides.com\/de\/team-aneta-kropicka\/#person"}},{"@type":"BreadcrumbList","@id":"https:\/\/one-peptides.com\/de\/retatrutide-vs-tirzepatide-triple-vs-dual-agonism-in-anti-obesity-pharmacology\/#breadcrumblist","itemListElement":[{"@type":"ListItem","@id":"https:\/\/one-peptides.com\/de\/#listItem","position":1,"name":"Home","item":"https:\/\/one-peptides.com\/de\/","nextItem":{"@type":"ListItem","@id":"https:\/\/one-peptides.com\/de\/category\/metabolism\/#listItem","name":"Metabolic research"}},{"@type":"ListItem","@id":"https:\/\/one-peptides.com\/de\/category\/metabolism\/#listItem","position":2,"name":"Metabolic research","item":"https:\/\/one-peptides.com\/de\/category\/metabolism\/","nextItem":{"@type":"ListItem","@id":"https:\/\/one-peptides.com\/de\/retatrutide-vs-tirzepatide-triple-vs-dual-agonism-in-anti-obesity-pharmacology\/#listItem","name":"Retatrutide vs Tirzepatide \u2014 triple vs dual agonism in anti-obesity pharmacology"},"previousItem":{"@type":"ListItem","@id":"https:\/\/one-peptides.com\/de\/#listItem","name":"Home"}},{"@type":"ListItem","@id":"https:\/\/one-peptides.com\/de\/retatrutide-vs-tirzepatide-triple-vs-dual-agonism-in-anti-obesity-pharmacology\/#listItem","position":3,"name":"Retatrutide vs Tirzepatide \u2014 triple vs dual agonism in anti-obesity pharmacology","previousItem":{"@type":"ListItem","@id":"https:\/\/one-peptides.com\/de\/category\/metabolism\/#listItem","name":"Metabolic research"}}]},{"@type":"Organization","@id":"https:\/\/one-peptides.com\/de\/#organization","name":"One-Peptides","url":"https:\/\/one-peptides.com\/de\/","logo":{"@type":"ImageObject","url":"https:\/\/one-peptides.com\/wp-content\/uploads\/2024\/09\/cropped-Image-1-e1751599136894.png","@id":"https:\/\/one-peptides.com\/de\/retatrutide-vs-tirzepatide-triple-vs-dual-agonism-in-anti-obesity-pharmacology\/#organizationLogo","width":291,"height":113},"image":{"@id":"https:\/\/one-peptides.com\/de\/retatrutide-vs-tirzepatide-triple-vs-dual-agonism-in-anti-obesity-pharmacology\/#organizationLogo"},"legalName":"Joscur Limited","sameAs":["https:\/\/www.instagram.com\/one_peptides\/"],"contactPoint":{"@type":"ContactPoint","email":"contact@one-peptides.com","contactType":"customer service"},"parentOrganization":{"@type":"Organization","name":"Joscur Limited"}},{"@type":"Person","@id":"https:\/\/one-peptides.com\/de\/team-bartosz-bartczak\/#person","url":"https:\/\/one-peptides.com\/de\/team-bartosz-bartczak\/","name":"Bartosz Bartczak","image":{"@type":"ImageObject","@id":"https:\/\/one-peptides.com\/de\/retatrutide-vs-tirzepatide-triple-vs-dual-agonism-in-anti-obesity-pharmacology\/#authorImage","url":"https:\/\/secure.gravatar.com\/avatar\/18c5ebea790bc7a8bd4088066983b1a92e5db957aa4e5888766fe20b92c9cfe6?s=96&d=mm&r=g","width":96,"height":96,"caption":"Bartosz Bartczak"}},{"@type":"Person","@id":"https:\/\/one-peptides.com\/de\/team-aneta-kropicka\/#person","name":"Aneta Kropicka","honorificPrefix":"M.Pharm.","url":"https:\/\/one-peptides.com\/de\/team-aneta-kropicka\/"},{"@type":"WebPage","@id":"https:\/\/one-peptides.com\/de\/retatrutide-vs-tirzepatide-triple-vs-dual-agonism-in-anti-obesity-pharmacology\/#webpage","url":"https:\/\/one-peptides.com\/de\/retatrutide-vs-tirzepatide-triple-vs-dual-agonism-in-anti-obesity-pharmacology\/","name":"Retatrutide vs. Tirzepatide \u2014 Tri-Agonist vs. Dual Agonist","description":"Retatrutide vs. Tirzepatide \u2014 a comparison of the mechanism and clinical data. GLP-1\/GIP\/glucagon tri-agonist and GLP-1\/GIP dual agonist, Mounjaro\/Zepbound","inLanguage":"de-DE","isPartOf":{"@id":"https:\/\/one-peptides.com\/de\/#website"},"breadcrumb":{"@id":"https:\/\/one-peptides.com\/de\/retatrutide-vs-tirzepatide-triple-vs-dual-agonism-in-anti-obesity-pharmacology\/#breadcrumblist"},"author":{"@id":"https:\/\/one-peptides.com\/de\/team-bartosz-bartczak\/#person"},"creator":{"@id":"https:\/\/one-peptides.com\/de\/team-bartosz-bartczak\/#person"},"image":{"@type":"ImageObject","url":"https:\/\/one-peptides.com\/wp-content\/uploads\/2026\/06\/triple-g-vs-glp1gip.webp","@id":"https:\/\/one-peptides.com\/de\/retatrutide-vs-tirzepatide-triple-vs-dual-agonism-in-anti-obesity-pharmacology\/#mainImage","width":1536,"height":1024},"primaryImageOfPage":{"@id":"https:\/\/one-peptides.com\/de\/retatrutide-vs-tirzepatide-triple-vs-dual-agonism-in-anti-obesity-pharmacology\/#mainImage"},"datePublished":"2026-06-18T16:56:01+00:00","dateModified":"2026-10-04T10:27:29+00:00"},{"@type":"WebSite","@id":"https:\/\/one-peptides.com\/de\/#website","url":"https:\/\/one-peptides.com\/de\/","name":"One-Peptides","inLanguage":"de-DE","publisher":{"@id":"https:\/\/one-peptides.com\/de\/#organization"}}]},"og:locale":"de_DE","og:site_name":"One-Peptides -","og:type":"article","og:title":"Retatrutide vs. Tirzepatide \u2014 Tri-Agonist vs. Dual Agonist","og:description":"Retatrutide vs. Tirzepatide \u2014 a comparison of the mechanism and clinical data. GLP-1\/GIP\/glucagon tri-agonist and GLP-1\/GIP dual agonist, Mounjaro\/Zepbound","og:url":"https:\/\/one-peptides.com\/de\/retatrutide-vs-tirzepatide-triple-vs-dual-agonism-in-anti-obesity-pharmacology\/","og:image":"https:\/\/one-peptides.com\/wp-content\/uploads\/2026\/06\/triple-g-vs-glp1gip.webp","og:image:secure_url":"https:\/\/one-peptides.com\/wp-content\/uploads\/2026\/06\/triple-g-vs-glp1gip.webp","og:image:width":1536,"og:image:height":1024,"article:published_time":"2026-06-18T16:56:01+00:00","article:modified_time":"2026-10-04T10:27:29+00:00","twitter:card":"summary_large_image","twitter:title":"Retatrutide vs. Tirzepatide \u2014 Tri-Agonist vs. Dual Agonist","twitter:description":"Retatrutide vs. Tirzepatide \u2014 a comparison of the mechanism and clinical data. GLP-1\/GIP\/glucagon tri-agonist and GLP-1\/GIP dual agonist, Mounjaro\/Zepbound","twitter:image":"https:\/\/one-peptides.com\/wp-content\/uploads\/2026\/06\/triple-g-vs-glp1gip.webp"},"aioseo_meta_data":{"post_id":"2072","title":"Retatrutide vs. Tirzepatide \u2014 Tri-Agonist vs. Dual Agonist","description":"Retatrutide vs. Tirzepatide \u2014 a comparison of the mechanism and clinical data. GLP-1\/GIP\/glucagon tri-agonist and GLP-1\/GIP dual agonist, Mounjaro\/Zepbound","keywords":null,"keyphrases":{"focus":{"keyphrase":"Retatrutide vs. Tirzepatide","score":57,"analysis":{"keyphraseInTitle":{"score":9,"maxScore":9,"error":0},"keyphraseInDescription":{"score":9,"maxScore":9,"error":0},"keyphraseLength":{"score":9,"maxScore":9,"error":0,"length":3},"keyphraseInURL":[],"keyphraseInIntroduction":{"score":3,"maxScore":9,"error":1},"keyphraseInSubHeadings":{"score":3,"maxScore":9,"error":1},"keyphraseInImageAlt":{"score":3,"maxScore":9,"error":1},"keywordDensity":{"score":0,"type":"low","maxScore":9,"error":1}}},"additional":[]},"primary_term":null,"canonical_url":null,"og_title":null,"og_description":null,"og_object_type":"default","og_image_type":"default","og_image_url":null,"og_image_width":null,"og_image_height":null,"og_image_custom_url":null,"og_image_custom_fields":null,"og_video":"","og_custom_url":null,"og_article_section":null,"og_article_tags":null,"twitter_use_og":false,"twitter_card":"default","twitter_image_type":"default","twitter_image_url":null,"twitter_image_custom_url":null,"twitter_image_custom_fields":null,"twitter_title":null,"twitter_description":null,"schema":{"blockGraphs":[],"customGraphs":[],"default":{"data":{"Article":[],"Course":[],"Dataset":[],"FAQPage":[],"Movie":[],"Person":[],"Product":[],"ProductReview":[],"Car":[],"Recipe":[],"Service":[],"SoftwareApplication":[],"WebPage":[]},"graphName":"BlogPosting","isEnabled":true},"graphs":[]},"schema_type":"default","schema_type_options":null,"pillar_content":false,"robots_default":true,"robots_noindex":false,"robots_noarchive":false,"robots_nosnippet":false,"robots_nofollow":false,"robots_noimageindex":false,"robots_noodp":false,"robots_notranslate":false,"robots_max_snippet":"-1","robots_max_videopreview":"-1","robots_max_imagepreview":"large","priority":null,"frequency":"default","local_seo":null,"seo_analyzer_scan_date":"2026-10-04 10:27:51","breadcrumb_settings":null,"limit_modified_date":false,"open_ai":null,"ai":{"faqs":[],"keyPoints":[],"schemas":[],"titles":[],"descriptions":[],"socialPosts":{"email":{"subject":"","preview":"","content":""},"linkedin":[],"twitter":[],"facebook":[],"instagram":[]}},"created":"2026-06-18 16:33:33","updated":"2026-10-04 11:13:13","focus_keyword":"Retatrutide vs. Tirzepatide","additional_keywords":null,"truseo_locale":null},"aioseo_breadcrumb":"<div class=\"aioseo-breadcrumbs\"><span class=\"aioseo-breadcrumb\">\n\t<a href=\"https:\/\/one-peptides.com\/de\/\" title=\"Home\">Home<\/a>\n<\/span><span class=\"aioseo-breadcrumb-separator\">\u00bb<\/span><span class=\"aioseo-breadcrumb\">\n\t<a href=\"https:\/\/one-peptides.com\/de\/category\/metabolism\/\" title=\"Metabolic research\">Metabolic research<\/a>\n<\/span><span class=\"aioseo-breadcrumb-separator\">\u00bb<\/span><span class=\"aioseo-breadcrumb\">\n\tRetatrutide vs Tirzepatide \u2014 triple vs dual agonism in anti-obesity pharmacology\n<\/span><\/div>","aioseo_breadcrumb_json":[{"label":"Home","link":"https:\/\/one-peptides.com\/de\/"},{"label":"Metabolic research","link":"https:\/\/one-peptides.com\/de\/category\/metabolism\/"},{"label":"Retatrutide vs Tirzepatide \u2014 triple vs dual agonism in anti-obesity pharmacology","link":"https:\/\/one-peptides.com\/de\/retatrutide-vs-tirzepatide-triple-vs-dual-agonism-in-anti-obesity-pharmacology\/"}],"_links":{"self":[{"href":"https:\/\/one-peptides.com\/de\/wp-json\/wp\/v2\/posts\/2072","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/one-peptides.com\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/one-peptides.com\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/one-peptides.com\/de\/wp-json\/wp\/v2\/users\/31"}],"replies":[{"embeddable":true,"href":"https:\/\/one-peptides.com\/de\/wp-json\/wp\/v2\/comments?post=2072"}],"version-history":[{"count":10,"href":"https:\/\/one-peptides.com\/de\/wp-json\/wp\/v2\/posts\/2072\/revisions"}],"predecessor-version":[{"id":2849,"href":"https:\/\/one-peptides.com\/de\/wp-json\/wp\/v2\/posts\/2072\/revisions\/2849"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/one-peptides.com\/de\/wp-json\/wp\/v2\/media\/2073"}],"wp:attachment":[{"href":"https:\/\/one-peptides.com\/de\/wp-json\/wp\/v2\/media?parent=2072"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/one-peptides.com\/de\/wp-json\/wp\/v2\/categories?post=2072"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/one-peptides.com\/de\/wp-json\/wp\/v2\/tags?post=2072"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}